Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 5 Breast Neoplasms 5 Neoplasms 3 Ovarian Neoplasms 2 Neoplasm Metastasis 2 mCRPC 1 Wilms Tumor 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Sarcoma, Ewing 1 Sarcoma 1 Rhabdomyosarcoma 1 Rhabdoid Tumor 1 Pathologic Complete Response 1 Pancreatic Neoplasms 1 Osteosarcoma 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Neuroblastoma 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Leukemia, Myeloid, Acute 1 Hepatoblastoma 1 Hemangiosarcoma 1 Extensive Stage Lung Small Cell Carcinoma 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Adenocarcinoma 1

Interventions

pembrolizumab 26 Paclitaxel 25 Carboplatin 19 Bevacizumab 13 Specimen Handling 11 Magnetic Resonance Spectroscopy 9 Doxorubicin 8 Cisplatin 8 Taxes 7 Biopsy 7 olaparib 6 lenvatinib 6 Fulvestrant 6 durvalumab 5 dostarlimab 5 Nivolumab 5 Megestrol Acetate 5 Letrozole 5 Gemcitabine 5 Docetaxel 5 trastuzumab deruxtecan 4 Trastuzumab 4 Tirzepatide 4 Progestins 4 Medroxyprogesterone Acetate 4 Fluorouracil 4 palbociclib 3 ipatasertib 3 atezolizumab 3 abemaciclib 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Endometrial Neoplasms × talazoparib × 90 days × Clear all

NCT04486352 2026-04-01

EndoMAP

Alliance Foundation Trials, LLC.

Phase 1/2 Recruiting

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡